Table 5.
Interleukin-6 (IL-6) and risk of venous thromboembolism in a portion of our cohort (n = 200).
| Variable | No. | 2-Year cumulative rate, % | Univariate |
Multivariate |
||
|---|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |||
| Age | 0.57 | 0.78 | ||||
| <60 years | 99 | 12.4 | 1 | 1 | ||
| ⩾60 years | 101 | 9.1 | 0.78 (0.33–1.86) | 0.87 (0.34–2.22) | ||
| CA-125 levels | 0.19 | 0.95 | ||||
| ⩽35 IU/L | 15 | 0.0 | 1 | 1 | ||
| >35 IU/L | 185 | 11.6 | 22.7 (0.02–28,568) | na | ||
| Thrombocytosisa | 0.028 | 0.31 | ||||
| No | 122 | 7.0 | 1 | 1 | ||
| Yes | 78 | 16.7 | 2.58 (1.07–6.22) | 1.65 (0.63–4.33) | ||
| Residual tumour size after surgery | 0.96 | 0.84 | ||||
| >1 cm | 63 | 11.5 | 1 | 1 | ||
| ⩽1 cm | 137 | 10.0 | 1.03 (0.39–2.67) | 1.11 (0.41–3.04) | ||
| Stage-specific histologic subtype | 0.039 | |||||
| Advanced SOC | 151 | 13.4 | 1 | 1 | ||
| Advanced OCCC | 6 | 40.0 | 5.07 (1.13–22.7) | 3.43 (0.76–15.6) | 0.11 | |
| Early-stage SOC | 11 | 0.0 | 0 | na | 0.99 | |
| Early-stage OCCC | 32 | 17.5 | 2.17 (0.77–6.13) | 4.00 (1.25–12.8) | 0.019 | |
| IL-6 levels prior to treatmentb | 0.012 | |||||
| <5 pg/mL | 68 | 1.4 | 1 | 1 | ||
| 5–19.9 pg/mL | 79 | 14.0 | 9.66 (1.25–74.9) | 7.98 (0.99–64.0) | 0.051 | |
| ⩾20 pg/mL | 53 | 17.1 | 12.1 (1.53–95.5) | 8.90 (1.04–76.0) | 0.046 | |
The log-rank test was used for univariate analysis and Cox proportional hazards regression modelling was used for multivariate analysis.
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous thromboembolism; SOC, serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma; na, not available.
a
Platelet count ⩾ 400 × 109/L.
b
IL-6 levels were grouped into lower third (1–33‰, <5 pg/mL), mid third (34–66‰, 5–19.9 pg/mL) and upper third (⩾67‰, ⩾20 pg/mL).